[1] Vivar N, Van Vollenhoven RF. Advances in the treatment of rheumatoid arthritis. F1000Prime Rep. 2014;6:31.
[2] 莫选荣,罗心静.类风湿性关节炎发病机制的研究进展[J].医学临床研究,2007;(2):336-340.
[3] Kasperkovitz PV, Timmer TC, Smeets TJ, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum. 2005;52(2): 430-441.
[4] 谢庆云,魏萌,张波,等.外周血炎性细胞因子与类风湿关节炎[J].中国组织工程研究,2012(42):7945-7950.
[5] Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164(10):4991-4995.
[6] Ito H, Hamerman JA. TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol. 2012;42(1):176-185.
[7] Gao X, Dong Y, Liu Z, et al. Silencing of triggering receptor expressed on myeloid cells-2 enhances the inflammatory responses of alveolar macrophages to lipopolysaccharide. Mol Med Rep. 2013;7(3):921-926.
[8] Chen Q, Zhang K, Jin Y, et al. Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance. Am J Respir Crit Care Med. 2013;188(2):201-212.
[9] Kleinberger G, Yamanishi Y, Suarez-Calvet M, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243): 243r-286r.
[10] Crotti TN, Dharmapatni AA, Alias E, et al. The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther. 2012;14(6):R245.
[11] Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1977; 146(3):857-868.
[12] 陈欢雪,王晓非.间充质干细胞移植治疗4种风湿性疾病:10年资料分析[J].中国组织工程研究,2014,(14):2263-2268.
[13] Kaur K, Kalra S, Kaushal S. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther. 2014;36(7):1074-1086.
[14] Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85(3):307-310.
[15] Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223: 252-270.
[16] 杨慧君,钱玉中,杨继章,等.胶原性关节炎大鼠滑膜组织细胞因子基质金属蛋白酶3和组织金属蛋白酶抑制剂1表达的变化[J].中国组织工程研究与临床康复,2007(32):6402-6405.
[17] McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-442.
[18] Pap T, Meinecke I, Muller-Ladner U, et al. Are fibroblasts involved in joint destruction? Ann Rheum Dis. 2005;64 Suppl 4:v52-v54.
[19] Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010; 233(1):233-255.
[20] Yoshida K, Hashimoto T, Sakai Y, et al. Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis. J Immunol Res. 2014; 2014:282495.
[21] 侯春凤,孙闵,李树杰,等.小干扰RNA对人类风湿关节炎患者滑膜细胞基因表达的影响[J].中国组织工程研究,2013,(46):8062- 8068.
[22] 燕鹏.肿瘤坏死因子-α抑制剂(益赛普)治疗类风湿关节炎的meta分析[D].济南:山东大学,2008.
[23] 刘彧,韩星海,孟济明.生物制剂在类风湿关节炎治疗中的应用[J].中华风湿病学杂志,2003(05):300-302.
[24] Augello A, Tasso R, Negrini SM, et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007;56(4):1175-1186.
[25] Sharif O, Knapp S. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology. 2008;213(9-10):701-713.
[26] N'Diaye EN, Branda CS, Branda SS, et al. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol. 2009;184(2):215-223.
[27] Rajagopalan P, Hibar DP, Thompson PM. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369(16): 1565-1567.
[28] Sun M, Zhu M, Chen K, et al. TREM-2 promotes host resistance against Pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway. Invest Ophthalmol Vis Sci. 2013;54(5):3451-3462.
[29] Turnbull IR, Gilfillan S, Cella M, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177(6): 3520-3524.
[30] Ford J W, McVicar D W. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009;21(1): 38-46.
[31] Suchankova M, Bucova M, Tibenska E, et al. Triggering receptor expressed on myeloid cells-1 and 2 in bronchoalveolar lavage fluid in pulmonary sarcoidosis. Respirology. 2013;18(3):455-462.
[32] Piccio L, Buonsanti C, Mariani M, et al. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol. 2007;37(5):1290-1301.
[33] Oh JH, Yang MJ, Heo JD, et al. Inflammatory response in rat lungs with recurrent exposure to welding fumes: a transcriptomic approach. Toxicol Ind Health. 2012;28(3): 203-215.
[34] 秦涛.TREM-1、TREM-2在非酒精性脂肪性肝炎时肝组织表达的研究[D].太原:山西医科大学,2012.
[35] 沈茜.TREM-2在非小细胞肺癌中的表达及意义[D].杭州:浙江大学,2009.
[36] Paradowska-Gorycka A, Jurkowska M. Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. Hum Immunol. 2013;74(6):730-737.
[37] Sun GY, Guan CX, Zhou Y, et al. Vasoactive intestinal peptide re-balances TREM-1/TREM-2 ratio in acute lung injury. Regul Pept. 2011;167(1):56-64.
[38] Humphrey MB, Daws MR, Spusta SC, et al. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res. 2006;21(2): 237-245.
[39] Colonna M, Turnbull I, Klesney-Tait J. The enigmatic function of TREM-2 in osteoclastogenesis. Adv Exp Med Biol. 2007;602:97-105.
[40] Otero K, Shinohara M, Zhao H, et al. TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol. 2012;188(6): 2612-2621.
[41] 李淑芬.TREM-2对小鼠成纤维细胞增殖与凋亡的影响及VIP的调控[D].长沙:中南大学,2012.
[42] Park M, Yi JW, Kim EM, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) promotes adipogenesis and diet-induced obesity. Diabetes. 2015;64(1):117-127.
[43] Lis K, Kuzawińska O, Ba?kowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2014; 10(6):1175-1185.
[44] Wang Y, Wang S, Li Y, et al. Therapeutic effect of Cryptotanshinone on collagen-induced arthritis in rats via inhibiting nuclear factor kappa B signaling pathway. Transl Res. 2014. doi: 10.1016/j.trsl.2014.12.004.
[45] Goedken ER, Argiriadi MA, Banach DL, et al. Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol. J Biol Chem. 2015;290(8):4573-4589.
[46] Xu CP, Li X, Hu YJ, et al. Quantitative proteomics reveals ELP2 as a regulator to the inhibitory effect of TNF-α on osteoblast differentiation. J Proteomics. 2015;114:234-2346.
[47] Meier FM, McInnes IB. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol. 2014;28(4):605-624.
[48] Klein K, Kabala PA, Grabiec AM, et al. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-205809.
[49] Damento G, Kavoussi SC, Materin MA, et al. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2014;89(11):1481-1486.
[50] Liu Q, Zhao J, Tan R, et al. Parthenolide inhibits pro-inflammatory cytokine production and exhibits protective effects on progression of collagen-induced arthritis in a rat model. Scand J Rheumatol. 2014:1-10.
[51] Fuggle NR, Howe FA, Allen RL, et al. New insights into the impact of neuro-inflammation in rheumatoid arthritis. Front Neurosci. 2014;8:357.
[52] Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014;111(47):16814-16819.
[53] Wadström H, Eriksson JK, Neovius M, et al. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)? Scand J Rheumatol. 2015;44(1): 22-28.
[54] Zheng Y, Hou J, Peng L, et al. The pro-apoptotic and pro-inflammatory effects of calprotectin on human periodontal ligament cells. PLoS One. 2014;9(10):e110421 |